Evaluation of the clinical effectiveness of HIV antigen/antibody screening using a chemiluminescence microparticle immunoassay.
Human immunodeficiency virus (HIV) screening assays have improved from single-antigen detection to detection of antigen-antibody combinations. However, concerns have been raised over the potential for false-positive results in antigen-antibody combination assays. The present study investigated the clinical effectiveness of HIV antigen/antibody (HIV Ag/Ab) combination screening by chemiluminescence microparticle immunoassay (CMIA) in over 88,000 samples from an HIV low-prevalence area of Beijing, China. The HIV Ag/Ab CMIA screening results were consistent with those obtained by Western blot and HIV-RNA testing, and had an accuracy of 99.74% (Kappa index=0.98). False-positive results were more common for women affected by clinical interfering factors (e.g., kidney disease, tumors) than for men (80.95% vs. 15.09%, P<0.001). When CMIA signal-to-cutoff ratio (S/CO) was 11.26, the sensitivity and specificity were highest (100%, 99.43%), and the area under the ROC curve (AUC) was 0.998. Specimens that were negative by CMIA (S/CO <1) were all negative by HIV-RNA testing. These results indicate that HIV Ag/Ab CMIA has a good clinical performance; however, some clinical interfering factors should be considered in HIV low-prevalence areas for their potential to skew testing results.